Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography.


Journal

European urology oncology
ISSN: 2588-9311
Titre abrégé: Eur Urol Oncol
Pays: Netherlands
ID NLM: 101724904

Informations de publication

Date de publication:
04 2023
Historique:
received: 29 08 2022
revised: 10 01 2023
accepted: 03 02 2023
medline: 18 4 2023
pubmed: 5 3 2023
entrez: 4 3 2023
Statut: ppublish

Résumé

Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has greater specificity and sensitivity for detection of extraprostatic prostate cancer (PCa) at presentation than conventional imaging. Although the long-term clinical significance of acting on these findings is unknown, it has been shown that the risk of upstaging is prognostic for long-term outcomes in men with high-risk (HR) or very high-risk (VHR) PCa. We evaluated the association between the risk of upstaging on PSMA PET and the Decipher genomic classifier score, a known prognostic biomarker in localized PCa that is being evaluated for its predictive ability to direct systemic therapy intensification. In a cohort of 4625 patients with HR or VHR PCa, the risk of upstaging on PSMA PET was significantly correlated with the Decipher score (p < 0.001). These results should be seen as hypothesis-generating and warrant further studies on the causal pathways linking PSMA findings, Decipher scores, extraprostatic disease, and long-term clinical outcomes. PATIENT SUMMARY: We found significant correlation between the risk of having prostate cancer outside the prostate gland on a sensitive scan (based on prostate-specific membrane antigen [PSMA]) at initial staging and the Decipher genetic score. The results warrant further studies on the causal pathways between PSMA scan findings, Decipher scores, disease outside the prostate, and long-term outcomes.

Identifiants

pubmed: 36870853
pii: S2588-9311(23)00041-X
doi: 10.1016/j.euo.2023.02.009
pii:
doi:

Substances chimiques

Gallium Radioisotopes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

224-227

Informations de copyright

Copyright © 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Clayton P Smith (CP)

Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.

James A Proudfoot (JA)

Veracyte, Inc, South San Francisco, CA, USA.

Paul C Boutros (PC)

Department of Human Genetics, University of California-Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA.

Robert E Reiter (RE)

Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA.

Luca Valle (L)

Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.

Matthew B Rettig (MB)

Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA; Division of Hematology/Oncology, Department of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

Nicholas G Nickols (NG)

Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.

Felix Y Feng (FY)

Department of Radiation Oncology, University of California-San Francisco, San Francisco, CA, USA.

Paul L Nguyen (PL)

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Himanshu Nagar (H)

Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.

Daniel E Spratt (DE)

Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

Gert Attard (G)

University College London Cancer Institute, London, UK.

Adam Weiner (A)

Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA.

Joanne B Weidhaas (JB)

Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

T Martin Ma (TM)

Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.

Elai Davicioni (E)

Veracyte, Inc, South San Francisco, CA, USA.

Michael Xiang (M)

Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA.

Amar U Kishan (AU)

Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California-Los Angeles, Los Angeles, CA, USA. Electronic address: aukishan@mednet.ucla.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH